Get the Stockscreener App
58.83
0.32%
-0.19
After Hours:
59.66
0.83
+1.41%
Royalty Pharma Plc stock is traded at $58.83, with a volume of 2.11M.
It is down -0.32% in the last 24 hours and up +8.38% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$59.02
Open:
$59.56
24h Volume:
2.11M
Relative Volume:
0.59
Market Cap:
$26.08B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
30.81
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
+1.12%
1M Performance:
+8.38%
6M Performance:
+45.62%
1Y Performance:
+60.78%
1-Day Range:
$58.51
$59.72
1-Week Range:
$56.90
$59.72
52-Week Range:
$34.08
$59.72
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
58.83 | 26.08B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma PLC $RPRX Shares Sold by KBC Group NV - MarketBeat
RPHC5035520 Bond Profile — Key Metrics - TradingView
ABN Amro Investment Solutions Purchases New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
RPHC6166014 Bond Profile — Key Metrics - TradingView
Inceptionr LLC Increases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
CI Investments Inc. Has $8.33 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
RPHC5222528 Bond Profile — Key Metrics - TradingView
RPHC6166014 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5035520 Bond Risk Profile - TradingView
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
RPHC5237354 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237354 Bond Risk Profile - TradingView
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
RPHC5237354 Bond Profile — Key Metrics - TradingView
RPHC5035520 Bond Coupon Profile — Rate & Payments - TradingView
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma - marketscreener.com
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
177,500 Shares in Royalty Pharma PLC $RPRX Acquired by Andra AP fonden - MarketBeat
Press Release: Royalty Pharma Declares Third Quarter 2026 Dividend - 富途牛牛
Royalty Pharma PLC (RPRXN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
RPHC6166013 Bond Risk Profile - TradingView
RPHC6166013 Bond Profile — Key Metrics - TradingView
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com UK
Royalty Pharma PLC (RPRX) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com South Africa
Royalty Pharma PLC (RPRX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - marketscreener.com
Royalty Pharma deal includes $125M upfront for heart antibody - Stock Titan
Royalty Pharma PLC $RPRX Shares Bought by Swiss National Bank - MarketBeat
Mediolanum International Funds Ltd Sells 40,296 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPRX|Royalty Pharma PLC|Price:59.050|Chg%:+0.030 - TradingKey
SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc. - MarketBeat
How (RPRX) Movements Inform Risk Allocation Models - Stock Traders Daily
Hsbc Holdings PLC Acquires 1,486,020 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824521 Bond Profile — Key Metrics - TradingView
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.52 |
100,000 |
5,651,813 |
459,399 |
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.46 |
30,000 |
1,693,658 |
40,000 |
0.26%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):